Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases.
Theoharides, Theoharis C, Tsilioni, Irene · Current topics in medicinal chemistry · 2018 · DOI
Quick Summary
This review examines how certain molecules in the brain called cytokines and neuropeptides may trigger inflammation in specific brain areas (the hypothalamus and amygdala) in people with ME/CFS. The authors propose that a natural compound called tetramethoxyluteolin (a modified form of a plant-derived substance called luteolin) might help reduce this inflammation and improve symptoms. The study suggests this compound could be delivered directly into the nasal passages to reach the brain more effectively.
Why It Matters
This work addresses a critical gap in ME/CFS research by proposing a testable biological mechanism (brain inflammation via mast cell and microglial activation) and identifying a specific compound for investigation. For patients, it offers a potential therapeutic avenue based on neurobiological hypotheses that could explain multiple ME/CFS symptoms and open pathways for future clinical trials.
Observed Findings
Neuropeptides and cytokines can stimulate mast cells and microglia to produce focal brain inflammation in hypothalamic and amygdalar regions.
Tetramethoxyluteolin demonstrates inhibitory effects on the proposed inflammatory cascade involving IL-33 and related signaling pathways in experimental systems.
Tetramethoxyluteolin has greater metabolic stability and oral absorption compared to its parent compound, luteolin.
Brain inflammation has been associated with neurological and psychiatric features commonly observed in ME/CFS and autism spectrum disorder.
Inferred Conclusions
Focal brain inflammation triggered by cytokine-neuropeptide interactions may underlie a substantial portion of ME/CFS and ASD symptomatology.
Tetramethoxyluteolin could serve as a promising anti-inflammatory agent for neurodegenerative and neuroinflammatory diseases due to its pharmacokinetic properties.
Intranasal delivery of tetramethoxyluteolin may provide therapeutic benefit by targeting brain inflammation while minimizing systemic effects.
Remaining Questions
Has tetramethoxyluteolin been tested in any clinical trials in humans with ME/CFS, and what is the evidence of its efficacy and safety?
Can the proposed inflammatory mechanism be validated using objective biomarkers (e.g., CSF cytokine levels, neuroimaging) in ME/CFS patients?
What This Study Does Not Prove
This review does not establish that tetramethoxyluteolin is effective in humans with ME/CFS—no clinical trial data is presented. It does not prove that the proposed inflammatory mechanism is the primary driver of ME/CFS (correlation vs. causation remains unresolved), nor does it validate any objective biomarkers for the disease. The evidence remains largely theoretical and mechanistic.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →